Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple-negative breast cancer: results from the phase 3 randomised KEYNOTE-119 study.

Autor:	Schmid, Peter1 (AUTHOR) p.schmid@qmul.ac.uk, Lipatov, Oleg2 (AUTHOR), Im, Seock-Ah3 (AUTHOR), Goncalves, Anthony4 (AUTHOR), Muñoz-Couselo, Eva5 (AUTHOR), Lee, Keun Seok6 (AUTHOR), Tamura, Kenji7 (AUTHOR), Testa, Laura8 (AUTHOR), Witzel, Isabell9 (AUTHOR), Ohtani, Shoichiro10 (AUTHOR), Turner, Nicholas11 (AUTHOR), Zambelli, Stefania12 (AUTHOR), Harbeck, Nadia13 (AUTHOR), Andre, Fabrice14 (AUTHOR), Dent, Rebecca15 (AUTHOR), Mejia, Jaime A.16 (AUTHOR), Zhou, Xuan17 (AUTHOR), Haiderali, Amin18 (AUTHOR), Nguyen, Allison Martin19 (AUTHOR), Cortes, Javier20 (AUTHOR)
Zdroj:	European Journal of Cancer. Dec2023, Vol. 195, pN.PAG-N.PAG. 1p.
Databáze:	Academic Search Ultimate
Externí odkaz:	Zobrazit plný text záznamu Full Text from ScienceDirect